PNLIP and obesity disorder: Orlistat is a clinically available anti-obesity drug that acts as inhibitor of gastric and pancreatic lipase and has been shown to block the absorption of dietary fats of about 30% at the therapeutic oral dosage of 120 mg per three times a day.